Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Bandwidth of ANA/AA: technologies
- Bandwidth of ANA/AA: autoantigens, diseases
- Why order an ANA
- ABIM choosing wisely
- Unlike Abele's experience
- Main problems of ANA testing
- ANA progress
- Summary: ANA testing in clinical practice
- The ANA is the 'gold standard' (1)
- The ANA is the 'gold standard' (2)
- Seven studies comparing IIF ANA to SPA
- Conclusions: ANA -IIF vs. SPA CTD screen
- Brief history: classification criteria
- ANA and SLE classification criteria
- Converging megatrends
- Deep neural network
- Biomarker diagnostic technologies
- Simple patient stratification based on ANA
- Complex patient stratification based on ANA
- Patient stratification based on ANA
- Biomarker driven nomenclature and stratification
- ANA positive healthy individuals
- Disease prevention
- Key points: ANA testing
- Disclosure
- Acknowledgements
- Thank you
Topics Covered
- ANA IFA as the ‘gold standard’ test
- Considerations of the seronegative gap in SLE and related conditions
- The future of ANA testing
- ANA testing dependent on solid phase MAAAA
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Fritzler, M.J. (2020, June 30). The past, present & future of ANA testing: changing bandwidth and future of ANA [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 13, 2024, from https://doi.org/10.69645/LJRI2297.Export Citation (RIS)
Publication History
Financial Disclosures
- Disclosure Statement: Dr. Fritzler received honoraria and research gifts in kind from Inova Diagnostics/Werfen International; Euroimmun AG-A Perkin Elmer Company; BioRad and Alexion Canada. He is Medical Director of Mitogen Advanced Diagnostics Laboratory. He does not own or trade shares in any companies referred to in this presentation.
The past, present & future of ANA testing: changing bandwidth and future of ANA
Published on June 30, 2020
33 min
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. This is the second part of my talk on
anti-nuclear antibody and related antibody testing.
In the first part, we briefly reviewed the history of autoantibody testing,
some of the changes that have occurred in the explosion of
autoantibodies in systemic lupus and related diseases,
the challenges that are being faced in terms of
ANA interpretation of the indirect immunofluorescence assay.
I now want to address the changing bandwidth of ANA testing,
talk about the gold standard of ANA testing,
and then the future of ANA testing in the context of precision health.
0:37
First of all, speaking to the changing bandwidth of ANA and autoantibody testing,
dating back to the 1950s in the history of
the ANA tests that I reviewed earlier, all the way to the present in 2019.
You can see the technologies as they changed over time,
starting with the LE cell,
moving to double immunodiffusion, indirect immunofluorescence,
ELISA, line immunoassays, addressable laser bead
immunoassays and multi-analyte arrays in the 2019 era.
1:11
Over the years along with the technology creep,
the bandwidth is not only changed in terms of the technologies that are being used,
but also in the diseases that anti-nuclear antibody testing has used them.
That is shown near the top of the slide with the arrow shaded in yellow,
where initially the anti-nuclear antibody test was used
as a diagnostic approach for systemic lupus or SLE.
Over the years, this has changed to include Sjögren's syndrome,
mixed connective tissue disease, sub-acute cutaneous lupus,
systemic sclerosis, overlap syndrome,
anti-phospholipid syndrome, inflammatory myopathies,
autoimmune liver disease and so on.
The point is, in addition to the technology changing bandwidth
of diseases that we now use anti-nuclear antibody testing in,
has also dramatically expanded.
Along with that, as I've already reviewed with you,
there's been a change in the different autoantibody targets that we now can identify
and only a few of those are shown in the dark box as starting in the early 60s and 70s,
SNP and histone, DNA,
to a broadening array of auto-antibodies such as Sm or RNP to cardiolipin,
chromatin, topo 1, centromere,
RNAP and so on.
Along with the changing profile of diseases that are seen,
the clinicians who ordered the ANA test is also
dramatically widened as shown in the box as well.
Initially, the anti-nuclear antibody tests
were primarily used by rheumatologists and immunologists.
Today, as shown in the far right,
that is now markedly expanded to include primary care, hematology,
oncology, obstetrics, cardiology, neurology,
psychiatry, and respiratory or pulmonary medicine.
The bandwidth of autoantibody testing has changed in a number of dimensions,
which includes the technologies used,
the diseases that are addressed by anti-nuclear antibody testing,
the different targets that have been described,
but also in the clinical setting in which these autoantibodies are tested and
the clinicians who see these patients with this wide range of ANA tests related diseases.
Hide